While downregulation of HLA-I occurs in some tumors, most tumor cells express sufficient HLA-I to inhibit NK cells, and chronic inflammation within the tumor microenvironment can further induce HLA-I expression via IFN-γ, contributing to NK cell resistance (39, 40). The gene discussed is IFNG; the disease is neoplasm.